Dysregulation of IL-2/IL-2R system alters proliferation of early activated CD4+ T cell subset in patients with end-stage renal failure

Evaluation of Delayed-Type Hyper Sensitivity Skin Test In CKD Patients: Significance of Candin Test

“…cases with positive induration have higher eGFR values. The result is in conformity with several studies; which showed defective cooperation between T cells and APCs (especially monocytes) leading to subnormal proliferation and interferon-y and interleukin (IL)-2 production, and thus reduced cellular immunity and DTH response [11,12].…”

CD4+/FOXP3+ Regulatory T Cells in End-Stage Kidney Disease: Molecular Pathways Trough Cell-Cycle Arrest and Apoptosis

“…However, patients with ESKD show an early activation of CD4 + T cells and impaired proliferation ability in conjunction with an impaired IL-2 pathway [11]. Indeed, part of activated CD4 + T cells from these patients, which did not express the CD25 activation marker, are dysfunctional, do not proliferate and are apoptotic [11].…”

“…However, patients with ESKD show an early activation of CD4 + T cells and impaired proliferation ability in conjunction with an impaired IL-2 pathway [11]. Indeed, part of activated CD4 + T cells from these patients, which did not express the CD25 activation marker, are dysfunctional, do not proliferate and are apoptotic [11]. Thus, in uremic patients, oxLDL seem to play a specific role in the frequencies and phenotypes of CD4 + /CD25 + /CD127¯ Tregs, which distinctly discriminates between nTreg and effector cell subsets [15].…”

“…The analysis of the other markers such as HLA-DR (late-activated T cells), CD45RO (postactivated memory helper T cells), CD11a (postactivated cytotoxic T cells) and CD28 (postactivated lymphokine-producing cytotoxic T cells) does not provide any argument for further overall Tcell activation. This might indicate that the type of activation observed generally in T cells from uremic patients was somehow aborted or inefficient [11,42].…”

“…Patients with ESKD chronically hemodialyzed present changes not only in T cell immunity but also in lipid profile [11,12]. Apart from their immune function, circulating T cells may actively participate to atherogenesis, and treatments aimed at reducing T cell activation and apoptosis in patients with ESKD reduce the risk of developing cardiovascular disease [13].…”